Momenta planning follow-on

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said late Tuesday it is planning a follow-on underwritten by UBS. Further details were not disclosed. In July, FDA approved an ANDA from Momenta and the Sand...